Eli Lilly opens retatrutide early access to small patient group
The program makes the investigational triple agonist available to a limited number of patients ahead of any FDA decision on the drug.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 4 03:00 ETSource: NCHStats
The wire
- 01Eli Lilly has opened an early access route to retatrutide for a small group of patients before the investigational incretin has been approved by the FDA.
- 02Prescribers and telehealth operators fielding retatrutide requests now have a sanctioned channel to point to, in a market where gray-market versions of the compound circulate.
- 03Eligibility criteria, size of the cohort and timing of any regulatory filing are not detailed in the report; early access is not approval and supply remains restricted.
From the source
Read at nchstats.comEli Lilly Retatrutide Early Access Opens to a Small Group of Patients Before FDA Approval
